Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Accord and hipra enter into exclusive distribution agreement to commercialise hipra's covid-19 vaccine
Saturday, August 05, 2023Accord Healthcare Ltd Accord and HIPRA today announced that they have entered into an exclusive distribution agreement to commercialise HIPRAs COVID vaccine in the United Kingdom UK
ACCORD and HIPRA Enter into Exclusive Distribution Agreement to Commercialise HIPRA's COVID-19 vaccine (BIMERVAX®) in the United Kingdom
Saturday, August 05, 2023Accord Healthcare Ltd Accord and HIPRA today announced that they have entered into an exclusive distribution agreement to commercialise HIPRAs COVID vaccine in the United Kingdom UK
BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies
Friday, August 04, 2023BlueRock Therapeutics LP a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG and bitbio the company coding human cells for novel cures today announced a collaboration and option agreement for the disco...
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Friday, August 04, 2023Agios Pharmaceuticals Inc Nasdaq AGIO has entered into an exclusive worldwide license agreement with Alnylam Pharmaceuticals Inc under which Agios will acquire the rights to develop and commercialize Alnylams novel preclinical siRNA targeting TMPRSS
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
Friday, August 04, 2023Mind Medicine MindMed Inc NASDAQ MNMD NEO MMED the Company or MindMed a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders announced today that it has entered into a license agreement with Cat...
Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Thursday, August 03, 2023Grnenthal GmbH CEO Gabriel Baertschi a global sciencebased privatelyowned pharmaceutical company and Kyowa Kirin Co Ltd TSE President and CEO Masashi Miyamoto Kyowa Kirin a Japanbased global specialty pharmaceutical company today announced the succes...
PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer
Thursday, August 03, 2023PacBio a leading developer of highquality highly accurate sequencing solutions today announced that it has entered into an agreement to acquire Apton Biosystems Inc Apton a BayAreabased company developing a high throughput shortread sequencer using s...
Prometheus Laboratories Announces Collaboration with Fresenius Kabi on Anser Testing
Thursday, August 03, 2023Prometheus Laboratories Inc Prometheus today announced a collaboration with Fresenius Kabi to support the validation of and access to Anser therapeutic drug monitoring TDM services for eligible patients receiving the Fresenius Kabi biosimilar IDACIO...
Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets
Thursday, August 03, 2023Charles River Laboratories International Inc NYSE CRL announced the planned openings of Charles River Accelerator and Development Lab CRADL locations in Seattle and Philadelphia expanding contract vivarium space for the biopharmaceutical industry
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
Tuesday, August 01, 2023ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc NASDAQ PNT POINT a company accelerating the discovery development and global access to lifechanging radiopharmaceuticals today announc...
